Nevertheless, compelling data supports the notion that dual IC inhibition, particularly incorporating PD-1, significantly surpasses single IC interventions in boosting tumor-associated CD8+ T cell efficacy, both in vitro and in vivo (83). The gene discussed is CD8A; the disease is neoplasm.